Baxdrostat in Phase 2 Clinical Trial Proves Effective, Safe in Treatment-resistant Hypertension
Baxdrostat shows potential to represent the first new class of antihypertensive agents approved since 2017.
Fully Remote Intervention for Hypertension, Lipids Proves Feasible, Successful in Large, Diverse Health Care Network
The Mass General Brigham clinical intervention and study included 10 000 participants and resulted in significant reductions in SBP/DBP and LDL-C.
AACE President Discusses New Guideline Recommendations for Cardiorenal Protective Therapy in T2D
Use of GLP-1 mimetics and SGLT-2 inhibitors for cardiorenal protection in T2D patients is backed by robust clinical trial evidence, says AACE President Sethu Reddy, MD.
5 Cities Benefitting Most & Least from New Medical Debt Credit Reporting Changes
Equifax, Experian, and TransUnion announced 3 major changes to medical debt reporting, expected to remove ~70% of medical collection debt tradelines from consumer credit reports.
Management of Type 2 Diabetes Complications, Comorbidities Focus of AACE 2022 Guideline Update
AACE president Dr Sethu Reddy highlights evidence-based updates, including selection of diabetes medication based on comorbidities and new agents to treat DKD and elevated lipids.
Sotagliflozin Cuts Risk by >50% for Heart Failure Readmission, CV Death in Phase 3 SOLOIST-WHF Trial
In the SOLOIST-WHF trial, risk for HF readmission and CV death were reduced by more than 50% at 30- and 90-days after hospital discharge.
Lifestyle Interventions Based on Obesity Phenotypes Significantly More Effective vs Standard Methods, Study Shows
The novel approach to targeted obesity treatment could improve weight loss outcomes, suggest findings from ObesityWeek® 2022.
Moderate-to-heavy Alcohol Consumption in Young Adulthood May Lead to Early Stroke, Warn New Study Findings
Study authors saw a positive dose-response relationship driven by hemorrhagic stroke in young adults who were moderate-to-heavy drinkers in their 20s and 30s.
Remote Electrical Neuromodulation Device Effective for Migraine Prevention in Pivotal Trial
The Nerivio REM device demonstrated a statistically significant reduction in migraine days/month vs a placebo device in both chronic and episodic migraine.
Empagliflozin Reduced Risk of Renal Disease Progression, CV Death Across CKD Spectrum in EMPA-KIDNEY
Empagliflozin achieved a decrease in risk of kidney disease progression of 28% vs placebo in the most diverse population of patients in an SGLT-2 inhibitor trial.
AACE President Sethu Reddy, MD, Highlights Updated 2022 Diabetes Guidelines for Primary Care
Reddy talks about the value of A1c vs results of an OGTT for T2D diagnosis, about glycemic targets and patient safety, hyperglycemia during pregnancy, and more in our interview.
Apixaban May be the Safer DOAC in Afib, Suggests First Large Comparative Analysis
Apixaban was associated with up to a 28% lower risk of GI bleeding vs the 3 other direct oral anticoagulants in the first large-scale comparative analysis.
7 RSV Myths and Facts: Prepare for the New Wave of Misinformation
RSV is back for the 2022-23 respiratory virus season and is unfamiliar to many. Click through this quick collection of myths already in circulation to prepare.
Semaglutide 2.4 mg (Wegovy) Yields "Amazing" Weight Loss in Adolescents, Similar to Adult Response
Semaglutide 2.4 mg (Wegovy) weight loss benefits in adolescents mirror those seen in adults, according to phase 3a trial findings presented at ObesityWeek® 2022.
Practice-related Factors in Primary Care May Limit Weight Management Services Offered
ObesityWeek® 2022. Primary care clinicians report providing on average just 70% of a wide range of clinical weight management services, according to a new survey.
RSV Older Adult Vaccine Candidate from GSK Wins FDA Priority Review, PDUFA Date Set
The FDA accepted the GSK BLA and granted priority review to what could be the first vaccine approved against RSV in adults aged ≥60 years, according to the company.
Maternal RSV Vaccine Prevents Infection in Infants, Pfizer Announces
Topline phase 3 trial data showed 81.8% efficacy for the maternal vaccine against severe RSV-related illness in infants from birth through first 90 days of life.
Investigational Glucagon Receptor/GLP-1 Receptor Dual Agonist Bests Semaglutide for Weight Loss in T2D Patients
ObesityWeek® 2022. Coagonism of the glucagon and GLP-1 receptors appears to result in greater weight loss than GLP-1 receptor agonism alone, study suggests.
Low Uptake of Antiobesity Medications Explored in Patient Perception Survey
ObesityWeek® 2022. Low awareness of antiobesity medications and concerns about cost, side effects revealed as barriers to wider uptake in a new study.
Black Patients with Afib Significantly Less Likely to Receive Oral Anticoagulation at Hospital Discharge
Black patients were also at significantly increased risk of stroke, bleeding, and mortality vs White patients 1 year following discharge.
Adult RSV Vaxx Gets EMA Nod: Can USA be Far Behind?
The GSK RSV vaccine candidate has received favorable international regulatory attention which may be an auspicious sign for the US.
Finerenone Mitigates HF, CV Risk Across Baseline Renal Function in Patients with T2D
The findings underscore the importance of routine eGFR and UACR screening in primary care to ensure early detection of CKD and avoid related adverse outcomes.
Low-carbohydrate Diet Could Help Improve Untreated HbA1c of 6.0% to 6.9%
In patients with prediabetes and untreated type 2 diabetes, a reduced carbohydrate diet improved HbA1c and other metabolic markers vs a usual diet.
Recombinant Zoster Vaccine Protection Durable at 10 Years, New Study Finds
Efficacy of the RZV vaccine against herpes zoster infection remained >80% in a long-term follow-up study representing 10 years since initial immunization.
High- vs Standard-dose Dexamethasone Could Pose Risks for Ventilated COVID-19 Patients
High-dose dexamethasone is often prescribed for critically ill COVID-19 patients although there is no evidence for its efficacy. A new study looked deeper.
COVID-19 Vaccine Status Update: Adults, Bivalent Boosters, Kids, & Teens
The overall US COVID-19 vaccination picture has both bright spots and dark areas. Get a quick look at details from the most recent KFF Vaccine Monitor survey.
High-dose Influenza Vaccine Consistently More Effective vs Standard-dose in Older Adults: Meta-analysis
The high-dose influenza vaccines provided greater relative vaccine effectiveness/efficacy vs standard dose in a cohort of more than 45 million.
COPD: Delay Before Start of Triple Therapy May Increase Risk for Exacerbations
CHEST. After a moderate COPD event, treatment with TT within 30 days significantly reduced risk for exacerbation over 12 months vs treatment after 30 days.
Primary Care is the Likely "Home" for Long COVID Care: A Conversation with AAFP Board Chair Sterling Ransone, Jr, MD
AAFP Board Chair Ransone points to recent data that show two-thirds of long COVID patients are already treated in primary care settings.
US FDA Grants EUA for Novavax COVID-19 Booster Shot
Another choice of booster may help increase follow-up vaccination among the 50% of US adults who have yet to get a first booster dose.
